SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 14, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today that it has promoted Richard T. Kloos , M.D., to executive medical director, overseeing Veracyte’s global medical affairs in all clinical areas addressed by the company’s expanding menu of
PROCURE study will capture insights from 180 European breast cancer specialists, to develop consensus and recommendations SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 11, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today the initiation of a European study that will utilize the Delphi
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Sep. 4, 2020-- Veracyte, Inc . (Nasdaq: VCYT), a global genomic diagnostics company, announced today that Bonnie H. Anderson , chairman and chief executive officer, is scheduled to participate in two upcoming virtual investor conferences: Baird’s 2020
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 24, 2020-- Veracyte, Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, announced today that it has been awarded a Top Workplaces 2020 honor by the Bay Area News Group for the seventh consecutive year.
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 7, 2020-- Veracyte, Inc. (Nasdaq: VCYT) announced today the closing of its public offering of 6,900,000 shares of common stock, including 900,000 shares sold upon full exercise of the underwriters’ option to purchase additional shares, at a price
ePosters presented during ATS 2020 Virtual conference SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 5, 2020-- Veracyte, Inc . (Nasdaq: VCYT) announced today that data presented at the American Thoracic Society 2020 Virtual conference reinforce the potential clinical value of the company’s
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 5, 2020-- Veracyte, Inc . (Nasdaq: VCYT) today announced the publication of new data demonstrating that the Percepta ® classifier significantly reduces invasive procedures in lung cancer diagnosis by classifying nearly 40 percent of patients as
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 4, 2020-- Veracyte, Inc. (Nasdaq: VCYT) (the “Company”) today announced the pricing of an underwritten public offering of 6,000,000 shares of its common stock at a public offering price of $30.00 per share.
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Aug. 3, 2020-- Veracyte, Inc. (Nasdaq: VCYT) (the “Company”) today announced that it has commenced an underwritten public offering of 6,000,000 shares of its common stock. All of the shares are being offered by Veracyte .
Revenue of $20.7 Million and Genomic Testing Volume of 5,379 Company Advances Pipeline and Global Expansion Strategy Conference Call and Webcast Today at 4:30 p.m. ET SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Jul. 30, 2020-- Veracyte, Inc . (Nasdaq: VCYT) today announced financial results for
The information in our press releases and webcasts should be considered accurate only as of the date of the press release or presentation. We disclaim any obligation to supplement or update the information in these press releases or presentations.
